We claim:

1. A compound of Formula I



(I)

wherein,-

R is independently

- hydroxy,
- oxo,
- halo,
- cyano,
- nitro,
- C_1-C_{10} alkyl,
- C_1-C_{10} haloalkyl,
- CF_3,
- NR^1R^1,
- SR^1,
- OR^1,
- SO_2R^2,
- $OCOR^2$,
- NR^1COR^2,
- COR^2,
- $NR^1SO_2R^2$,
- phenyl, or
- a 5- or 6-membered heterocycle with from 1 to 4 heteroatoms selected from O, S, and N;

each cyclic moiety being optionally substituted with

- hydroxy,
- R^1,
- halo,
- cyano,

- NR^1R^1,
- SR^1,
- CF_3,
- OR^1,
- C_3-C_8 cycloalkyl,
- NR^1COR^2,
- COR^2,
- SO_2R^2,
- $OCOR^2$,
- $NR^1SO_2R^2$,
- C_1-C_{10} alkyl, or
- C_1-C_{10} alkoxy;

R^1 is

- hydrogen,
- $(CH_2)_d$-O-$(CH_2)_dR^5$ where each d is selected independently, or
- C_1-C_{10} alkyl optionally substituted with 1 to 4 substituents each independently selected from
  - hydroxy,
  - halo,
  - CO_2C_1-C_4-alkyl,
  - CO_2H,
  - C_1-C_{10} alkoxy,
  - $S(O)_bC_1$-C_{10} alkyl,
  - $S(O)_b$-phenyl optionally substituted with halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, SO_2-C_1-C_4alkyl, or CO_2 C_1-C_4alkyl; or
  - phenyl optionally substituted with CO_2C_1-C_4-alkyl, CO_2H, halo, or C_1-C_{10} alkyl;

  or
- C_3-C_8 cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1 to 4 substituents each independently selected from halo, nitro, oxo, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_1-C_{10} alkylthio, CO_2C_1-C_4-alkyl, and CO_2H,

and

when two R^1 groups are attached to N as NR^1R^1, these R^1 groups may form together with the nitrogen to which they are attached, a heterocyclic ring

containing 4 to 7 C atoms, 1 to 2 N atoms, and 0 to 1 O or S atoms;

R^2 is

- R^1,
- OR^1,
- NR^1R^1,
- $NHS(O)_b$phenyl optionally substituted with C_1-C_4 alkyl, C_1-C_4 alkoxy, halo or nitro;
- $NHS(O)_b$naphthyl,
- $NHS(O)_bC_1$-C_{10} alkyl optionally substituted with fluoro up to the perfluoro level, or
- a 5- or 6-membered heterocycle with one or more heteroatoms selected from O, S, and N, said heterocyclic moiety being optionally substituted with R^1;

R^3 is hydrogen, C_1-C_{10} alkyl, or COR^2;

R^4 is hydrogen, C_1-C_{10} alkyl, C_1-C_{10} alkyl-phenyl, or C_1-C_{10} alkyl-pyridyl;

R^5 is hydrogen or COOH;

R^6 is

- hydrogen,
- C_1-C_{10} alkyl optionally substituted with 1 to 4 substituents each independently selected from halo, phenyl, or phenyl-COR^2, or
- C_1-C_{10} alkyl-$S(O)_bC_1$-C_{10} alkyl optionally substituted with COR^2 or C_3-C_8 cycloalkyl;

Ar is

- phenyl optionally fused to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from O, S, and N, said bicyclic moiety being optionally fused to a phenyl, or
- a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, optionally fused to phenyl;

Y is

- halo,
- NO_2,
- R^6,
- SR^1,
- $S(O)_b$-phenyl-CO_2R^1,



where, when the two R^4 groups attached to the same C are both alkyl, they optionally may be joined so that, when taken together with the C to which they are attached, they form a spiro ring of 3, 5, or 6 C atoms, or where the R^4 attached to N and one R^4 attached to the adjacent C are both alkyl, they optionally may be joined so that, taken together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring;

with the proviso that when e is 1, at least one R^4 group must be C_1-C_{10} alkyl-phenyl or C_1-C_{10} alkyl-pyridyl, or two R^4 groups must form one of said spiro or heterocyclic ring moieties;

- phenyl optionally fused to one or two phenyl rings, or to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, or
- a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S and O, optionally fused to a phenyl ring,

each cyclic moiety being optionally substituted with one or more substituents independently selected from

- COR^2,
- $CONR^1S(O)_2R^9$,
- $COCH_2SO_2$-thiazolyl optionally substituted with alkyl or amino,
- halo,
- NO_2,
- OR^1,
- R^1,
- SR^1,
- O-C_1-C_6-alkyl substituted by C_3-C_6-cycloalkyl,
- O-phenyl optionally substituted by SO_2CH_3,
- SO_2NH_2,
- $SO_2NR^1R^7$,
- NR^1R^1,

- NR^1COC_1-C_6alkyl,
-  ,
-  ,
- C_1-$C_{10}COR^2$,
- phenyl optionally substituted with halo, C_1-C_4 alkyl, or C_1-C_4 alkoxy,
- tetrazolo;

R^7 is

- phenyl or heteroaryl containing 3-6 C and 1-3 O, N, or S atoms, each optionally substituted by C_1-C_4 alkyl, CN, NO_2, CO-C_1-C_4alkyl, C1-C_4 alkoxy, or C_1-C_4 haloalkyl,
- CO-R^8,
-  ,
-  ;

R^8 is

- C_1-C_6 alkyl optionally substituted with C_1-C_4 alkoxy, $N(CH_3)_2$,or one or two CF_3,
- C_3-C_6-cycloalkyl,
- phenyl optionally substituted with C_1-C_4 alkoxy, halo, or C_1-C_4 alkyl,
- NH-phenyl optionally substituted with C_1-C_4 alkyl, halo, C_1-C_4 alkoxy, or

C_1-C_4 haloalkoxy,

- NH-cyclohexyl;

R^9 is

- C_3-C_6 cycloalkyl,
- thienyl optionally substituted with C_1-C_4 alkyl or isoxazolyl,
- pyridyl optionally substituted with -SO_2-C_1-C_4alkyl,
- pyrazolyl optionally substituted with halo or C_1-C_4 alkyl,
- isoxazolyl optionally substituted with C_1-C_4 alkyl, or
- 

;

a is 0, 1, 2, 3, 4, or 5;

b is 0, 1, or 2;

d is 1, 2, or 3;

e is 1 or 2;

and pharmaceutically acceptable salts and esters thereof.

2. The compound of claim 1 wherein Y is

- halo,
- R^6,
- SR^1,
- $S(O)_b$-phenyl-CO_2R^1,
- phenyl optionally fused to one or two phenyl rings, or to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, or
- a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S and O, optionally fused to a phenyl ring,

each cyclic moiety being optionally substituted with one or more substituents independently selected from

- COR^2,
- halo,

- NO_2,
- OR^1,
- R^1,
- SR^1,
- $SO_2NR^1R^7$,
- NR^1R^1,
- NR^1COC_1-C_6alkyl,
- C_1-$C_{10}COR^2$,
- phenyl,
- tetrazolo;

and pharmaceutically acceptable salts and esters thereof.

3. The compound of claim 1 wherein Y is
    - phenyl optionally fused to one or two phenyl rings, or to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, or
    - a 5- or 6- membered heterocycle containing one or more heteroatoms each independently selected from N, S and O, optionally fused to a phenyl ring,

    each cyclic moiety being optionally substituted with one or more substituents independently selected from
    - COR^2,
    - halo,
    - NO_2,
    - OR^1,
    - R^1,
    - SR^1,
    - $SO_2NR^1R^7$,
    - NR^1R^1,
    - NR^1COC_1-C_6alkyl,
    - C_1-$C_{10}COR^2$,
    - phenyl,
    - tetrazolo;

    and d is 1 or 2;

and pharmaceutically acceptable salts and esters thereof.

4. The compound of claim 1 wherein

Y is

- phenyl optionally fused to one or two phenyl rings, or to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, or
- a 5- or 6- membered heterocycle containing one or more heteroatoms each independently selected from N, S and O, optionally fused to a phenyl ring,

each cyclic moiety being optionally substituted with one or more substituents independently selected from

- COR^2,
- halo,
- NO_2,
- OR^1,
- R^1,
- SR^1,
- $SO_2NR^1R^7$,
- NR^1R^1,
- C_1-$C_{10}COR^2$,
- phenyl,
- tetrazolo;

Ar is

- phenyl optionally fused to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from O, S, and N, said bicyclic moiety being optionally fused to a phenyl, or
- a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, optionally fused to phenyl;

and d is 1 or 2;

and pharmaceutically acceptable salts and esters thereof.

5. The compound of claim 1 wherein

Y is

- phenyl optionally fused to one or two phenyl rings, or to a 5- or 6-membered heterocycle containing one or more heteroatoms each independently selected from N, S, and O, or
- a 5- or 6- membered heterocycle containing one or more heteroatoms each independently selected from N, S and O, optionally fused to a phenyl ring,

each cyclic moiety being optionally substituted with one or more substituents independently selected from

- COR^2,
- halo,
- OR^1,
- R^1,
- NR^1R^1,

Ar is

- phenyl or
- a 5- or 6-membered heterocycle containing one or more N atoms;

a is 0, 1, 2, or 3; and

d is 1;

and pharmaceutically acceptable salts and esters thereof.

6. A compound selected from the group consisting of:

2-[4-(ethoxycarbonyl)phenoxy]-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid ;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-isobutylbenzoic acid;

N-{3-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoyl}-2-methylbenzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-isobutoxybenzoic acid;

N-{3-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoyl}-4-methoxybenzenesulfonamide;

N-{3-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoyl}-1-propanesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(4-methoxybenzoyl)benzenesulfonamide;

N-(2-cyano-4-nitrophenyl)-3-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

2-(4-chlorophenoxy)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

N-(4,6-dimethoxy-2-pyrimidinyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-(trifluoromethoxy)benzenesulfonamide;

2-(4-fluorophenoxy)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(3-methoxybenzoyl)benzenesulfonamide;

4-fluoro-N-{3-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoyl}benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-(4-methylphenoxy)benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-(2-phenylethyl)benzoic acid;

3-chloro-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

N-(4-fluorobenzoyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-methoxybenzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-phenoxybenzoic acid;

N-(4-cyanophenyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-(trifluoromethoxy)benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(4-methoxy-6-methyl-2-pyrimidinyl)-2-(trifluoromethoxy)benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(3,3,3-trifluoropropanoyl)benzenesulfonamide;

2-hydroxy-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

3-((1R)-2-{[((2R)-6-{4-[({[(4-fluorophenyl)amino]carbonyl}amino)sulfonyl]phenyl}-3,4-dihydro-2H-chromen-2-yl)methyl]amino}-1-hydroxyethyl)pyridine;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(2-pyrimidinyl)benzenesulfonamide;

N-benzoyl-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-propoxybenzoic acid;

N-({4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-pyridinyl}carbonyl)-4-methoxybenzenesulfonamide;

3-((1R)-1-hydroxy-2-{[((2R)-6-{4-[({[(4-methylphenyl)amino]carbonyl}amino)sulfonyl]phenyl}-3,4-dihydro-2H-chromen-2-yl)methyl]amino}ethyl)pyridine;

3-((1R)-2-{[((2R)-6-{4-[({[(4-chloro-2-methylphenyl)amino]carbonyl}amino)sulfonyl]phenyl}-3,4-dihydro-2H-chromen-2-yl)methyl]amino}-1-hydroxyethyl)pyridine;

N-(ethoxyacetyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

N-(3,3-dimethylbutanoyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-[4-(methylsulfonyl)phenoxy]benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-methylbenzoic acid;

4-{2-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]ethyl}benzoic acid;

N-(2,2-dimethylpropanoyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

3-[(1R)-2-({[(2R)-6-(4-{[(anilinocarbonyl)amino]sulfonyl}phenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}amino)-1-hydroxyethyl]pyridine;

2-ethoxy-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(4-methoxy-6-methyl-2-pyrimidinyl)benzenesulfonamide;

3-{(1R)-2-[({(2R)-6-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenyl]-3,4-dihydro-2H-chromen-2-yl}methyl)amino]-1-hydroxyethyl}pyridine;

N-(cyclopropylcarbonyl)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

2-chloro-5-fluoro-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

4-[(4-[R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-methylbenzoic acid;

2-fluoro-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-propoxybenzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-isopropoxybenzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(1,3-thiazol-2-yl)benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-(4-methoxyphenoxy)benzoic acid;

3-(cyclopropylmethoxy)-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzenesulfonamide;

5-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-4'-methyl-1,1'-biphenyl-2-carboxylic acid;

N-{6-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-pyridinyl}benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(3-pyridinyl)benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-methoxybenzoic acid;

4-chloro-N-{6-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-pyridinyl}benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-isobutoxybenzoic acid;

N-{6-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-3-pyridinyl}methanesulfonamide;

3-{2-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]ethyl}benzoic acid;

3-[(1E)-1-hexenyl]-4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

3-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-N-(2-pyrimidinyl)benzenesulfonamide;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2-(2-methoxyethoxy)benzoic acid;

4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-2,6-dimethylbenzoic acid;

4-[(2R)-2-({[(2R)-2-(6-amino-3-pyridinyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

3-[(2R)-2-({[(2R)-2-(6-amino-3-pyridinyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid;

(1R)-1-(6-amino-3-pyridinyl)-2-[({(2R)-6-[4-(1H-tetraazol-5-yl)phenyl]-3,4-dihydro-2H-chromen-2-yl}methyl)amino]ethanol;

5-{4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]phenyl}-3-phenyl-1,2l5,3l5,4-thiatriazole-2-carboxylic acid;

5-{4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]phenyl}-2-furoic acid;

5-{4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]phenyl}-2-thiophenecarboxylic acid;

5-{4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]phenyl}-3-thiophenecarboxylic acid;

4-{4-[(2R)-2-({[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]phenyl}-2-thiophenecarboxylic acid;

6-[(2R)-2-({[(2R)-2-(6-amino-3-pyridinyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]nicotinic acid;

5-[(2R)-2-({[(2R)-2-(6-amino-3-pyridinyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]nicotinic acid;

2-[(2R)-2-({[(2R)-2-(6-amino-3-pyridinyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]-4-pyridinecarboxylic acid;

1-({[(2R)-2-({[(2R)-2-(6-amino-3-pyridinyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]carbonyl}amino)cyclopropanecarboxylic acid; and

4-[(2R)-2-({[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid (Example 344).

7. A method of treating a beta-3 adrenergic receptor-mediated condition comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

8. A method of treating obesity comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

9. A method of treating diabetes comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

10. A method of treating a patient with impaired fasting glucose or impaired glucose tolerance comprising the step of administering to said patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

11. A method of treating gastrointestinal disorders comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

12. A method of treating hypertriglyceridemia, hypercholesteolemia, atherosclerotic disorders, or cardiovascular disorders comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

13. A method for lowering high-density lipoprotein levels comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

14. A method for treating urinary disorders comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 1.

15. The method of claim 14, wherein said urinary disorders is selected from the group consisting of pollakiuria and incontinence.

16. A method of treating a beta-3 adrenergic receptor-mediated condition comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

17. A method of treating obesity comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

18. A method of treating diabetes comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

19. A method of treating a patient with impaired fasting glucose or impaired glucose tolerance comprising the step of administering to said patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

20. A method of treating gastrointestinal disorders comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

21. A method of treating hypertriglyceridemia, hypercholesteolemia, atherosclerotic disorders, or cardiovascular disorders comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

22. A method for lowering high-density lipoprotein levels comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

23. A method for treating urinary disorders comprising the step of administering to a patient in need thereof a pharmaceutically effective amount of a compound of claim 6.

24. The method of claim 23, wherein said urinary disorders is selected from the group

consisting of pollakiuria and incontinence.

25. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt and esters thereof in combination with a pharmaceutically acceptable carrier.

26. A pharmaceutical composition for the treatment of obesity, diabetes, gastrointestinal disorders, hypertriglyceridaemia, hypercholesterolaemia, atherosclerosis, cardiovascular diseases, or urinary disorders comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt and ester thereof in combination with a pharmaceutically acceptable carrier.

27. A composition comprising an effective amount of a compound of claim 1 or a salt and esters thereof in combination with an inert carrier.

28. A pharmaceutical composition comprising an effective amount of a compound of claim 6 or a pharmaceutically acceptable salt and esters thereof in combination with a pharmaceutically acceptable carrier.

29. A pharmaceutical composition for the treatment of obesity, diabetes, gastrointestinal disorders, hypertriglyceridaemia, hypercholesterolaemia, atherosclerosis, cardiovascular diseases, or urinary disorders comprising an effective amount of a compound of claim 6 or a pharmaceutically acceptable salt and ester thereof in combination with a pharmaceutically acceptable carrier.

30. A composition comprising an effective amount of a compound of claim 6 or a salt and esters thereof in combination with an inert carrier.